Insider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 4,540 Shares of Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,540 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total transaction of $221,370.40. Following the sale, the insider now owns 258,073 shares in the company, valued at approximately $12,583,639.48. This represents a 1.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.07, for a total transaction of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.12, for a total value of $394,034.80.
• On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $56.26, for a total value of $374,972.90.

Apogee Therapeutics Stock Up 0.4 %

Shares of NASDAQ APGE opened at $44.50 on Friday. The firm has a 50-day simple moving average of $51.43 and a 200-day simple moving average of $48.28. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -18.39 and a beta of 2.30. Apogee Therapeutics, Inc. has a 52 week low of $20.78 and a 52 week high of $72.29.

Institutional Trading of Apogee Therapeutics

Hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP boosted its holdings in shares of Apogee Therapeutics by 35.7% during the 3rd quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock worth $282,798,000 after purchasing an additional 1,267,451 shares during the last quarter. Driehaus Capital Management LLC lifted its position in Apogee Therapeutics by 2.6% during the second quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock worth $83,338,000 after buying an additional 54,107 shares in the last quarter. Perceptive Advisors LLC boosted its stake in Apogee Therapeutics by 2.2% during the second quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock worth $82,857,000 after buying an additional 45,241 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in Apogee Therapeutics by 41.2% during the second quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company’s stock worth $32,908,000 after buying an additional 244,190 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Apogee Therapeutics by 11.2% in the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock valued at $48,401,000 after buying an additional 82,978 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on APGE. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Wedbush upped their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a research report on Monday, December 2nd. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research report on Thursday. Finally, Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $83.88.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.